N5，N10-亚甲基四氢叶酸还原酶基因多态性及血浆同型半胱氨酸与冠心病的关系

目的研究N5,N10-亚甲基四氢叶酸还原酶(MTHFR)基因C677T多态性、血浆同型半胱氨酸(Hcy)与冠心病的关系。方法选取2013年至2015年在我院住院的冠心病患者256例,按年龄分为60岁组(中青年组)107例及≥60岁组(老年组)149例,选取同期行健康体检的人群145例作为对照组,应用聚合酶链反应(PCR)技术和基因芯片分析技术检测MTHFR基因C677T多态性,应用高效液相色谱法测定血浆Hcy水平,分析不同组群之间MTHFR基因C677T多态性的分布及Hcy水平。结果 MTHFR基因分布频率:中青年组CC型、CT型、TT型基因频率分别为26.2%,43.9%,29.9%,C等位基因频率为48.1%,T等位基因频率为51.9%。中青年组CC型、CT型、TT型基因频率分别为35.6%,42.3%,22.1%,C等位基因频率为56.8%,T等位基因频率为43.2%。对照组CC型、CT型、TT型基因频率分别为37.9%,40.1%,21.4%,C等位基因频率为58.3%,T等位基因频率为41.7%。中青年组T等位基因频率明显高于对照组(χ~2=5.10,P=0.015),中青年组Hcy浓度明显高于对照组。老年组T等位基因频率与对照组比较差异无显著性(χ~2=0.147,P=0.382),两组间Hcy浓度差异无显著性。各组的TT基因型者血浆Hcy浓度均明显高于CC和TC基因型者(P0.01),而后两者间差异无显著性。结论 MTHFR基因TT型可导致Hcy水平明显升高,MTHFR基因C677T点突变仅与中青年组冠心病患者相关,与老年组冠心病患者无明显相关,Hcy水平升高及MTHFR基因T等位基因频率增高可能为中青年冠心病患者的危险因素,提示不同年龄阶段的冠心病患者发病的机制可能存在差异。     

亚甲基四氢叶酸还原酶基因多态性与原发性高血压患者合并冠心病的相关性研究

目的探讨N5,10-亚甲基四氢叶酸还原酶(MTHFR)C677T位点突变与河南豫北地区原发性高血压及其合并冠心病发病的关系。方法选择原发性高血压患者405例为高血压组,高血压合并冠心病患者400例为冠心病组,健康体检者400例为对照组。对3组MTHFR基因C677T多态性进行基因分型。结果冠心病组T等位基因频率和TT基因型频率明显高于高血压组和对照组(P<0.05)。冠心病组TT基因型患者TC和血浆同型半胱氨酸水平明显高于CC+CT基因型(P<0.05)。结论 MTHFR基因C677T多态性与原发性高血压患者冠心病的发生相关。     

内皮型一氧化氮合酶和N5，N10-亚甲基四氢叶酸还原酶基因多态性与苏皖地区汉族人群早发冠心病易感性的相关关系

目的 探讨内皮型一氧化氮合酶(eNOS)基因第7外显子G894T突变和N5,N10-亚甲基四氢叶酸还原酶(MTHFR)基因C677T突变与苏皖地区汉族人群早发冠心病(PCAD)发病的关系.方法 采用病例对照研究的方法,应用聚合酶链反应-限制性片长多态性(PCR-RFLP)技术,分别检测131例PCAD患者(PCAD组)和131例年龄、性别相匹配的无冠心病者(对照组)的eNOS和MTHFR基因的单核苷酸多态性,判定其基因型并统计各基因型及等位基因的频率.结果 eNOS基因G894T多态性在PCAD组和对照组中的基因型分布(x2=2.072,P=0.355)和T等位基因频率(x2=0.727,P=0.394)差异均无统计学意义.MTHFR基因C677T基因型在PCAD组CT和TT型分布均高于对照组(x2 =14.290,P=0.001),T等位基因频率亦高于对照组(x2=16.339,P =0.000),差异有显著性(P＜0.05).Logistic回归分析显示,携带MTHFR基因C677TTT基因型是PCAD发病的独立危险因素.结论 eNOS基因G894T多态性可能与苏皖地区汉族人群PCAD发病无关;MTHFR基因677C/T多态性的TT基因型可能增加苏皖地区汉族人群PCAD的患病风险,T等位基因可能是PCAD的遗传易感基因.     

同型半胱氨酸代谢关键酶基因多态性与2型糖尿病合并冠心病的关系

目的探讨我国北方地区汉族人同型半胱氨酸(Hcy)代谢相关酶(MTHFR C677T、CBS844ins68)基因多态性的特点及基因多态性与2型糖尿病(T2DM)合并冠心病(CHD)的关系。方法研究对象均为北方汉族人群,包括无血缘关系的105例T2DM合并CHD患者、125例单纯T2DM患者和91例健康对照组。应用分子生物学方法分析MTHFR C677T、CBS844ins68基因多态性。结果T2DM合并CHD组的T等位基因频率明显高于与对照组(45.3%vs34.6%,P<0.05),其中CT基因型频率高于对照组(58.1%vs38.5%,P<0.05),CC型频率明显低于对照组(25.7%vs46.2%,P<0.05)。CBS844ins68多态性三组CBS844ins68的基因型及等位基因频率差别均无统计学意义(均P>0.05)。Logistic回归分析显示MTHFR基因型的OR值为1.394,95%CI0.989-1.965(P=0.058);MTHFR677携带T基因(MTHFR CT基因型和TT基因型)的OR值为1.939,95%CI1.159-3.243(P=0.012);CBS的OR值为0.52,95%CI0.108-2.495(P=0.414)。结论MTHFR677携带T基因是我国北方地区汉族人T2DM合并CHD发生的独立危险因素,筛查MTHFR677T基因型可能在预防糖尿病合并冠心病的发生、发展过程中起到一定作用。     

甲烯四氢叶酸还原酶基因多态性与糖尿病大血管病变的关系研究

目的探讨甲烯四氢叶酸还原酶(MTHFR)基因C677T位碱基突变与2型糖尿病患者同型半胱氨酸(Hcy)水平和糖尿病大血管病变的关系。方法将患者分为对照组、糖尿病颈动脉内中膜厚度(IMT)正常组、糖尿病IMT增厚组。应用酶联免疫法测定Hcy水平,采用多聚酶链反应-限制性内切酶片段长度多态性技术(PCR-RFLP)检测MTHFRC677T基因型,用高分辨彩色多普勒检查颈动脉内中膜厚度(IMT)。结果糖尿病IMT增厚组MTHFR基因的TT基因型和T等位基因频率显著增高,与糖尿病IMT正常组及对照组存在统计学差异(P<0.05)。对照组与糖尿病IMT正常组之间T等位基因频率无统计学差异。MTHFR基因突变者血浆Hcy增高。糖尿病组MTHFR基因突变者IMT值明显高于无基因突变者。结论糖尿病IMT增厚组T等位基因频率增高。MTHFR基因C677T点突变组血浆Hcy水平升高,颈动脉IMT增厚。推测MTHFR基因C677T点突变可能是糖尿病合并大血管病变发病的重要遗传因素。     

血浆同型半胱氨酸及5,10-亚甲基四氢叶酸还原酶基因多态性与老年原发性高血压合并冠心病的关系

目的探讨血浆同型半胱氨酸(Hcy)水平及其代谢酶5,10-亚甲基四氢叶酸还原酶(MTHFR)基因多态性与老年原发性高血压合并冠心病的关系。方法选择2014年2月~2015年2月于玉林市第一人民医院心内科住院的老年原发性高血压患者共200例,其中男性115例,女性85例,平均年龄(67.52±3.53)岁。根据冠状动脉造影结果分为高血压组(100例)及冠状动脉粥样硬化性心脏病(冠心病)组(100例)。选取同时期的健康体检者100例为对照组。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)的方法检测3组MTHFR C677T基因型,同时检测Hcy水平。结果与对照组比较,高血压组和冠心病组血压、三酰甘油、总胆固醇、低密度脂蛋白胆固醇、Hcy均升高,差异有统计学意义(P均0.05)。高血压组MTHFR C677位点CC、CT和TT基因型频率分别为27.0%、50.0%和23.0%,C和T等位基因频率分别为52.0%和48.0%。冠心病组CC、CT和TT基因型频率分别为12.0%、55.0%和33.0%,C和T等位基因频率分别为39.5%和60.5%。对照组CC、CT和TT基因型频率分别为40.0%、45.0%和15.0%,C和T等位基因频率分别为62.5%和37.5%。冠心病组TT型基因频率及T等位基因频率均高于高血压组和对照组,差异有统计学意义(P均0.05)。冠心病组患者TT型Hcy水平高于CC型和CT型,差异有统计学意义(P均0.05)。结论 MTHFR C677T基因多态性中TT基因型可能是老年原发性高血压合并冠心病的一个重要遗传风险因子,T等位基因可能为该病的风险等位基因。     

宁夏回族冠心病患者亚甲基四氢叶酸还原酶基因多态性的研究

目的:研究亚甲基四氢叶酸还原酶(MTHFR)基因多态性与冠心病的关系.方法:应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析检测224例宁夏回族人群(冠心病组107例,对照组117例)MTHFR基因型及等位基因频率.结果:回族冠心病组和对照组MTHFR C677T CC,CT,TT 3种基因型分布(χ2=5.523,P=0.063)和等位基因频率分布(χ2=0.000,P=0.984)差异无统计学意义(P>0.05).结论:MTHFR基因多态性与冠心病无相关.     

帕金森病患者血清中Aβ1-42含量与MTHFRC677T基因多态性的关联性研究

目的探讨帕金森病(PD)患者血清β-淀粉样蛋白1-42(Aβ1-42)水平与N5,N10-亚甲四氢叶酸还原酶(MTHFR)基因多态性的关系。方法采用多聚酶链反应-限制性内切酶片段长度多态性技术(PCR-RFLP)分别检测PD患者50例和正常对照组50名MTHFR基因C677T位点多态性,同时测定血清Aβ1-42水平。结果PD组MTHFR基因TT型频率为32.0%,CT型频率为52.0%,CC型频率为16.0%;对照组分别为12.0%、56.0%和32.0%。PD组T等位基因频率为60.0%,C等位基因频率为40.0%;对照组分别为42.0%和58.0%。PD组MTHFR基因TT型患者血清Aβ1-42水平显著低于其他两型(F=4.831,P=0.012),CT型血清Aβ1-42水平显著低于CC型(P 0.05)。结论 PD患者MTHFR基因C677T突变与Aβ1-42水平显著相关,MTHFR基因突变可能是引起低Aβ1-42的一个重要遗传因素。     

同型半胱氨酸代谢相关酶基因多态性与心肌梗死关系的研究

目的研究同型半胱氨酸代谢相关酶亚甲基四氢叶酸还原酶(MTHFR)、胱硫醚-β-合成酶(CBS)及蛋氨酸合成酶(MS)基因多态性与心肌梗死(MI)相关性。方法应用聚合酶链反应-限制性内切酶片段长度多态性(PCR-RFLP)和聚合酶链反应(PCR)产物直接电泳技术,检测121例MI患者(患者组)和500例健康人(正常对照组)的MTHFR C677T、CBS 844 ins68和MS A2756G基因多态性。结果MTHFR C677T基因型分别为:CC野生型、CT杂合型、TT突变型。其在患者组分布频率分别为14.0%、46.3%、39.7%,T等位基因频率为62.85%,C等位基因频率为37.15%;正常对照组中为35.6%、44.0%2、0.4%,T等位基因频率为42.4%,C等位基因频率为57.6%。两组间各基因频率及等位基因频率比较差异均具有统计学意义(P<0.05)。而CBS 844ins 68和MSA2756G的基因型频率分布,两组间差异均无统计学意义(P>0.05)。结论MTHFR基因TT基因型,T等位基因与MI具有相关性;而CBS 844 ins68及MS A2756G基因多态性可能与MI发生无直接相关性。     

汉族脑卒中与N5,N10亚甲基四氢叶酸还原酶基因多态性的相关性研究

目的　探讨人体 N5,N1 0亚甲基四氢叶酸还原酶 (MTHFR)的基因多态性与脑卒中的遗传相关性。方法　采用限制性内切酶片段长度多态性方法 (PCR- RFLP) ,对 67例脑卒中病人和 78例健康人 MTHFR基因 C677T多态性位点进行检测。结果　病例组 MTHFR基因 T、C等位基因频率分别为 53%、47%,对照组为 39.7%、60 .3%,两组显著性差异 (χ2 =5.0 9,P<0 .0 5)。 TT型携带者较 CC型携带者罹患脑卒中的相对风险度为 2 .35(95%CI1 .0 2～ 5.43)。 T等位基因携带者较 C等位基因携带者罹患脑卒中的相对风险度为 1 .71 (95%CI1 .0 7～ 2 .74)。出血性卒中与缺血性卒中之间等位基因及等位基因型频率无明显差异。结论　脑卒中汉族人群 MTHFR基因 C677T位点多态性与脑卒中有相关性 ,MTHFR基因可能是脑卒中的一个易感基因。     

MTHFR基因多态性与冠心病的关系

目的研究天津地区人群N^5,N^10-亚甲基四氢叶酸还原酶（MTHFR）基因C677T多态性与冠心病的关系。方法应用聚合酶链反应（PCR）技术和限制性酶切片段长度多态性（RFLP）分析技术检测50例冠心病患者（冠心病组）和50例正常人（对照组）的MTHFR基因C677T多态性,应用高效液相色谱法测定血浆同型半胱氨酸（Hcy）水平,采用125I标记放免法测定血清叶酸浓度。结果1.冠心病组与对照组MTHFR基因频率分布不同（P〈0.05）,对照组CC型、TC型、TT型基因频率分别为52.0%,28.0%,20.0%,冠心病组分别为26.0%,44.0%,30.0%。冠心病组T等位基因频率为52.0%,C等位基因频率为48.0%,与对照组比较有显著性差异（P〈0.05）。2.两组的TT基因型者血浆Hcy浓度均明显高于CC和TC基因型者（P〈0.05）,而后两者间无显著性差异（P〉0.05）。3.冠心病组Hcy浓度高于照组（P〈0.05）,两组叶酸水平无显著性差异（P〉0.05）,血浆Hcy浓度与叶酸水平呈显著负相关（r分别为-0.617和-0.588,P〈0.05）。结论MTHFR基因C677T点突变与冠心病发病密切相关,MTHFR基因纯合突变是引起高Hcy血症的一个重要的遗传因素。     

The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease.

BACKGROUND: There are conflicting results on the relationship of N5,N10-methylenetetrahydrofolate reductase C677T gene variation in coronary artery disease and myocardial infarction. METHODS AND RESULTS: We analysed this gene variation in 2453 male Caucasians whose coronary anatomy was defined by coronary angiography. In the total sample, the C677T gene polymorphism was not associated with the presence or the extent of coronary artery disease (defined by the degree of vessel disease or by the coronary heart disease score according to Gensini). However, after excluding individuals with low risk profiles, an association between the C677T TT genotype and the Gensini score was found. This observation applies only to individuals (i) with high glucose levels, (ii) with low apolipoprotein Al/apolipoprotein B ratios, (iii) with low apolipoprotein Al/apolipoprotein B ratios and high lipoprotein (a) levels and (iv) with low apolipoprotein Al/apolipoprotein B ratios and high glucose concentrations. In patients with high glucose levels, the paraoxonase 191 A/B gene variation presupposed whether differences in Gensini scores between C677T C allele carriers and TT homozygotes became apparent, since only in paraoxonase 191 AA homoxygotes, but not in paraoxonase 191 B allele carriers, did C677T TT homozygotes have clearly higher Gensini scores than C allele carriers (two-way interaction; P = 0.013). The MTHFR C677T gene polymorphism was not associated with non-fatal myocardial infarction. CONCLUSION: The present study extends previous observations by the finding that carriers of the N5,N10-methylenetetrahydrofolate reductase C677T TT genotype with various coronary high risk profiles had clearly higher coronary heart disease scores than individuals with at least one C677T C allele.     

Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients

OBJECTIVE: Epidemiological studies have identified hyperhomocyst(e)inemia as an independent risk factor for atherosclerosis. The C677T variant of the methylenetetrahydrofolate reductase (MTHFR) gene, one of the key enzymes catalyzing remethylation of homocysteine, might play a role in the development of coronary heart disease (CHD). In this study, we examined the distribution of the MTHFR genotypes in the Chinese population and the association between the C677T variant and CHD in Chinese type 2 diabetic patients. METHODS: Two hundred and twenty-eight unrelated patients with type 2 diabetes mellitus (126 with coronary heart disease) and 114 healthy control subjects were recruited. The MTHFR genotype was analyzed by PCR followed by HinfI digestion. Plasma total homocysteine levels were measured using high-performance liquid chromatography (HPLC) with fluorescence detection. RESULTS: In 114 healthy control subjects, the frequency of the mutant T allele was 38.0%, comparable to that of a Hong Kong (Chinese) population. The genotype distribution did not differ between control subjects and type 2 diabetic patients (chi(2) = 3.67, P > 0.05). Genotypic analysis revealed that type 2 diabetic patients with CHD displayed a greater prevalence of T allele (45.2%) than type 2 diabetic patients without CHD (30.4%) (chi(2) = 8.72, P < 0.005). The odds ratio for CHD in type 2 diabetic patients in presence of T allele was 1.89 (CI 95%, 1.24-2.88). The MTHFR genotype were different between diabetic patients with and without CHD (chi(2) = 11.98, P < 0.005). Moreover, plasma homocysteine levels were markedly higher in individuals with TT genotype than those with CC or CT genotype or CC plus CT genotype. CONCLUSIONS: The C677T mutation of MTHFR gene is common in the Chinese population. MTHFR C677T gene polymorphism associated with a predisposition to increased plasma homocysteine levels could constitute a useful predictive marker for CHD in Chinese type 2 diabetic patients.     

C677T gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) in patients with myocardial infarction

Hyperhomocysteinemia is thought to be an independent risk factor for coronary heart disease. Increased plasma homocysteine level can result from malnutrition (e.g. folate deficiency) and/or genetic-related disturbances. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the synthesis of 5-methyltetrahydrofolate, the methyl donor for homocysteine remethylation to methionine. Transition of cytosine (C) to thymidine (T) at nucleotide position 677 of MTHFR gene causes alanine 226-to-valine substitution, and in consequence results in decreased enzyme activity and increased homocysteine level. Therefore, the aim of our study was to estimate the frequency distribution of C677T MTHFR polymorphism in patients with past myocardial infarction (MI), and to evaluate the association between this polymorphism and age of MI onset or left ventricular mass (LVM). The study was performed in 100 MI patients aged from 34 to 76 years and in control group consisted of 100 age- and gender-matched non-MI subjects. Applying PCR followed by Hinf I digestion of amplification products no significant difference in the frequency distribution of C677T MTHFR genotypes has been found between both groups (MI patients: 46% CC, 45% CT and 9% TT, and control group: 39% CC, 50% CT and 11% TT, respectively). No significant association between MTHFR genotypes and age of MI onset or LVM has been found in MI group. The results of our study suggest that C677T polymorphism of MTHFR gene is not a risk factor for myocardial infarction in Polish population.     

The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy

BACKGROUND: Poor glycaemic control, hypertension and duration of diabetes are risk factors for the development of diabetic nephropathy, but there may be genetic factors. Recently, a common C to T mutation at nucleotide position 677 of the MTHFR gene (MTHFR677C > T) has been reported to be correlated with hyperhomocysteinemia and the severity of coronary artery disease as macroangiopathy. We aim to investigate Turkish type 2 diabetic patients with/without diabetic nephropathy and healthy group and examine the contribution of the MTHFR gene polymorphism to the development of diabetic nephropathy. METHODS: DNA was extracted from peripheral leukocytes of the subjects. Genotyping of the MTHFR C677T polymorphism for all individuals was performed by melting curve analysis of the generated amplicons after real-time online PCR. RESULTS: This genotype distribution did not differ between control subjects and type 2 diabetic patients in which 6.8% were TT, 43.7% were CT and 49.5% were CC (chi2 = 0.201, p > 0.05). The frequency of the mutant T allele was 23.4% in diabetic patients with nephropathy versus 33.0% in those without nephropathy. The genotype frequencies were TT, 2.1%; CT, 46.6%; CC, 55.3% in diabetic patients with nephropathy versus TT, 10.7%; CT, 44.6%; CC, 44.6% in those without nephropathy. CONCLUSIONS: The MTHFR genotype and allele frequencies were not different between diabetic patients with and without nephropathy (chi2 = 3, 386, p > 0.005; chi2 = 2.320, p > 0.005, respectively). Therefore, we conclude that the MTHFR gene polymorphism is not associated with the development of diabetic nephropathy in Turkish type 2 diabetic patients.     

Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease

Although three common MTHFR polymorphisms (C677T, A1298C, T1317C) have been reported, only polymorphism C677T has been investigated intensively as a risk factor for coronary artery disease (CAD). We investigated polymorphism frequencies, allelic associations and the effect of the resulting MTHFR genotypes on total plasma homocysteine (tHcy) levels and on coronary risk in a case-control study with 1000 angiographically confirmed Middle-European CAD patients and 1000 matched controls. Three out of four theoretically possible MTHFR haplotypes were detected: *1 (677C, 1298A), *2 (677T, 1298A), and *3 (677C, 1298C). The frequencies were *1: 36.4 and 34.4%; *2: 30.8 and 32.3%; and *3: 32.8 and 33.3%, in cases and controls, respectively. Only one patient was heterozygous for 1317C. None of the six resulting genotypes showed significant influence on tHcy levels. Moreover, there was no significant association with CAD risk or with disease severity or early disease manifestation. In the subgroup presenting with acute coronary syndromes, MTHFR genotypes *2/*3 and *3/*3 were surprisingly underrepresented (relative risk of *3/*3, 0.40; 95% confidence interval 0.20-0.79, P=0.009). We conclude from our genotype-based analysis that, in this well-fed Middle-European population, the observed common allelic variants of the MTHFR gene have no significant influence on tHcy levels or on the chronic process of CAD development.     

冠心病患者血浆同型半胱氨酸及亚甲基四氢叶酸还原酶C677T基因多态性

目的比较不同冠心病类型及不同冠状动脉病变支数间血浆同型半胱氨酸水平差异,分析亚甲基四氢叶酸还原酶C677T基因突变对血浆同型半胱氨酸水平影响,及其与冠心病的关系.方法对经冠状动脉造影确诊的非冠心病74例、稳定型心绞痛32例、不稳定型心绞痛104例、急性心肌梗死25例采用改良高效液相色谱法测定同型半胱氨酸,聚合酶链反应-限制性内切酶法测定亚甲基四氢叶酸还原酶C677T基因型.结果血浆同型半胱氨酸水平冠心病组较非冠心病组显著增高,急性心肌梗死、不稳定型心绞痛组均较非冠心病组、稳定型心绞痛组显著增高,冠状动脉单支病变较正常、双支、三支病变组显著高.亚甲基四氢叶酸还原酶C677T基因纯合突变患者血浆同型半胱氨酸水平显著高于正常纯合子和杂合子患者.冠心病组亚甲基四氢叶酸还原酶C677T基因突变频率较对照组高,但无统计学意义.相关分析表明亚甲基四氢叶酸还原酶C677T基因突变与冠心病、同型半胱氨酸均无相关性.二元Logistic回归分析表明,高同型半胱氨酸血症致冠心病的OR值是1.138,亚甲基四氢叶酸还原酶C677T基因突变不是冠心病的独立危险因素.结论同型半胱氨酸可能是冠心病的独立危险因素,更可能是急性冠状动脉综合征的标志物.血浆同型半胱氨酸水平不与冠状动脉病变支数成正相关.亚甲基四氢叶酸还原酶C677T基因突变可能不是冠心病的独立危险因素及血浆同型半胱氨酸水平最关键的影响因素.     

MTHFR C677T基因多态性对稳定性冠心病患者叶酸降低同型半胱氨酸治疗的影响

目的探讨MTHFR C677T基因多态性对河南中部汉族稳定性冠状动脉粥样硬化性心脏病(冠心病)患者叶酸降低同型半胱氨酸(Hcy)治疗的影响。方法连续入选2018年4月至2018年9月于许昌市中心医院心血管内科住院的冠心病患者362例,依据MTHFR C677T基因检测结果分为A(CC型)、B(CT型)、C(TT型)三组,三组患者均在冠心病二级预防治疗的基础之上给予叶酸片降低Hcy治疗。记录患者应用叶酸治疗前、治疗后1个月、3个月血浆Hcy的变化,计算三组治疗3个月时降低Hcy治疗有效率,并对影响降低Hcy治疗的因素进行二元logistic回归分析。结果A、B、C三组分别有81例(22.4%)、169例(46.7%)和112例(30.9%)患者,三组治疗前血浆Hcy水平差异无统计学意义(P>0.05);三组治疗1个月和3个月血浆Hcy水平均低于治疗前,且A组治疗1个月时血浆Hcy水平低于B组和C组,差异均有统计学意义(P<0.05)。A组治疗有效率高于B组和C组,差异有统计学意义(P<0.05)。二元logistic回归分析显示,CC型患者降低Hcy治疗有效的可能是TT型患者的2.626倍,有熬夜史患者降低Hcy治疗有效的可能是无熬夜史患者的44.3%。结论MTHFR C677T基因多态性对稳定性冠心病患者叶酸降低Hcy治疗有影响,患者在降低Hcy治疗时应改变熬夜习惯。     

The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke

Homozygosity for the methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism may cause hyperhomocysteinaemia, a recognized risk factor for stroke, in individuals with folate deficiency. Homozygous sickle cell (SS) disease is associated both with increased demands for folic acid and a tendency to develop stroke. We therefore investigated a possible role of the MTHFR C677T polymorphism in SS disease patients with stroke. Investigation of the frequency of the polymorphism in 48 patients with stroke and in 48 age-, sex- and racially-matched SS controls without stroke failed to reveal a difference between the groups (Fisher exact test, P = 0.99). Homozygosity for the MTHFR C677T polymorphism is unlikely to be a risk factor for stroke in this population with SS disease.